The competition for the next generation of therapies has already begun. From metabolism and tumors to autoimmune diseases, from new targets for immunotherapy to AI driven drug development, from mitochondrial energy metabolism to the next generation of oral biologics - the boundaries of innovation are being redefined, and the possibilities for treatment are expanding at an unprecedented pace.

The complete schedule of the "Breakthrough Next Generation Innovative Therapy Special Session" was officially released today. The special session gathers top scientists and industry pioneers in the fields of metabolism, oncology, autoimmunity, immunology, etc., and conducts in-depth discussions on cutting-edge directions such as global progress in weight loss drugs, new immunotherapy platforms, mitochondrial targeted therapy, AI driven drug development, oral biopharmaceuticals, and next-generation ADC platforms, presenting a feast of ideas from scientific breakthroughs to industrial transformation.

On July 22-24, at the Shanghai National Convention and Exhibition Center, we sat down with those who define the next generation of therapies to explore the breakthrough path of innovative therapies.

Scan the code to register immediately
Early bird tickets are available for a limited time at a 25% discount!!

// Session Schedule//

Co-organized by:BrightGene, Laurel Venture Capital

14:00-17:50 / 22nd

14:00-14:30　The Path to Breakthroughs in Metabolic, Oncologic, and Autoimmune Diseases(Tentative)
Jiandong Yuan: Chairman, BrightGene

14:30-14:50　Global Progress in Anti-Obesity Drug R&D and China’s Contributions
Linong Ji: Director, Department of Endocrinology, Peking University People’s Hospital

14:50-15:10　Next-Generation MCE Innovative Drug Products(Tentative)
Yuehua Li: Chairman and General Manager, Leitekang Biopharmaceutical

15:10-15:30　Development of Rejuvenated Tumor-Reactive T-Cell Products(Tentative)
Weifeng Lai: Co-founder and CSO, Geek Gene

15:30-15:50　Novel Immunotherapy: DCAR Platform — Technology Innovation, Progress, and Market Opportunities
Renhuan Xu: Co-founder and CSO, Pinion

15:50-16:10　Break

16:10-16:30　The Immune System, Chronic Diseases, and Aging
Jianzhu Chen: Tenured Professor, MIT

16:30-16:50　Targeting Mitochondrial Energy Metabolism for Cancer Treatment
Yufeng Shi: Founder, Shijiang Bio; Professor, Tongji University

16:50-17:10　AI-Driven Development of Next-Generation Innovative Drugs
Jingfang Wang: Chairman and General Manager, MERNA

17:10-17:30　Next-Generation Oral Biologic Therapy Platform
Liu Dou: Founder, Oralead Pharma

17:30-17:50　Exploring Next-Generation ADC Platforms Driven by Modular Design
Yu Zhang: CEO, Nalian Bio